Angiocrine Bioscience, Inc.
|Program||Investigator||Award Title||Award Value|
|Late Stage Preclinical Projects||Paul Finnegan||Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy||$3,797,117|
|Clinical Trial Stage Projects||Paul Finnegan||AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110||$5,000,000|
|Clinical Trial Stage Projects||Edward Kavalerchik||AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205||$6,192,579|